AMA Delegates Reject Universal Newborn Cytomegalovirus Screening, Citing Cost and Logistics
The American Medical Association (AMA) House of Delegates voted against adopting a policy for universal newborn cytomegalovirus (CMV) screening during its 2023 meeting, according to a report by MedPage Today. The decision, which came after months of debate, reflects concerns over the financial burden and logistical challenges of implementing widespread screening programs.
CMV, a common virus, can cause severe complications in newborns, including hearing loss, developmental delays, and vision problems. While some states have introduced targeted screening initiatives, the AMA’s vote underscores the lack of consensus on a national approach.
What Is Cytomegalovirus (CMV) and Why Does It Matter?
CMV is a member of the herpesvirus family and infects 1 in 4 children by age 4, according to the Centers for Disease Control and Prevention (CDC). Most healthy individuals experience no symptoms, but congenital CMV—when a baby is infected in the womb—can lead to lifelong health issues. The CDC estimates that about 30,000 infants in the U.S. are born with congenital CMV annually, with 15% experiencing long-term disabilities.
Despite its prevalence, CMV screening is not routinely included in newborn blood tests, which typically check for conditions like phenylketonuria (PKU) or congenital hypothyroidism. Proponents argue that early detection could prevent irreversible damage, while opponents highlight the need for more research on cost-effectiveness.
Why Did the AMA Not Adopt Universal Screening?
The AMA’s decision followed a recommendation from its Council on Scientific Affairs, which cited “insufficient evidence” to support universal screening. Delegates expressed concerns about the financial strain on healthcare systems and the potential for false positives, which could lead to unnecessary medical interventions.
Dr. Sarah Lin, a pediatric infectious disease specialist at the University of California, San Francisco, noted that “screening programs require significant infrastructure, including specialized labs and follow-up care. Without a clear framework, widespread implementation risks disparities in access.”
The AMA’s stance contrasts with efforts in states like California and New York, which have launched pilot programs to screen newborns for CMV. California’s program, initiated in 2021, has identified hundreds of cases of congenital CMV, enabling early intervention.
What’s Next for CMV Screening Policy?
The AMA’s vote does not block individual states from pursuing their own screening policies, but it may slow federal funding for nationwide initiatives. Advocacy groups, including the National CMV Foundation, have called for more research into screening efficacy and cost-benefit analyses.
A 2022 study published in *Pediatrics* found that universal CMV screening could save $1.2 billion annually in healthcare costs by preventing long-term disabilities. However, the study’s authors acknowledged that “implementation challenges, such as test accuracy and resource allocation, must be addressed.”
Key Takeaways
- The AMA rejected universal newborn CMV screening due to cost and logistical concerns.
- Congenital CMV affects approximately 30,000 U.S. infants yearly, with 15% facing disabilities.
The debate over CMV screening highlights broader challenges in balancing public health priorities with fiscal and operational realities. As research continues, the push for standardized screening may gain momentum—but for now, the AMA’s decision leaves the path forward unclear.